Product Description
Vertex is developing VX-121 as a treatment for cystic fibrosis. (Sourced from: https://investors.vrtx.com/news-releases/news-release-details/vertex-initiate-phase-3-development-program-new-once-daily)
Mechanisms of Action: CFTR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Vertex
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Vertex presented P3 Cystic Fibrosis results on 2026-06-05 for Vanzacaftor
- Clinical Outcomes Reported - Vertex presented P3 Cystic Fibrosis results on 2025-06-04 for Vanzacaftor
- Clinical Outcomes Reported - Vertex presented P3 Cystic Fibrosis results on 2024-09-27 for Vanzacaftor
Highest Development Phases
Phase 3: Cystic Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07349394 |
VX25-121-014 | P1 |
Completed |
Cystic Fibrosis |
2026-02-28 |
50% |
2026-04-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06299709 |
VNZ/TEZ/D-IVA | P1 |
Completed |
Cystic Fibrosis |
2024-05-23 |
12% |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06299696 |
VX23-121-011 | P1 |
Completed |
Cystic Fibrosis |
2024-04-16 |
12% |
2024-05-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2018-002496-18 |
2018-002496-18 | P2 |
Active, not recruiting |
Cystic Fibrosis |
2019-11-02 |
2022-03-13 |
Treatments |
|
NCT05422222 |
VX21-121-105 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2030-06-30 |
32% |
2026-05-29 |
|
NCT05844449 |
VX22-121-106 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2029-07-30 |
6% |
2025-05-08 |
|
2024-514173-22-00 |
VX20-121-104 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2027-04-16 |
35% |
2025-05-02 |
|
2024-513754-29-00 |
VX21-121-105 | P3 |
Not yet recruiting |
Cystic Fibrosis |
2027-08-02 |
32% |
2025-05-02 |
Treatments |
NCT05444257 |
VX20-121-104 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2026-10-30 |
35% |
2025-09-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2022-503081-74-00 |
VX22-121-106 | P3 |
Recruiting |
Cystic Fibrosis |
2025-10-31 |
6% |
2025-05-02 |
Treatments |
2021-000712-31 |
2021-000712-31 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2024-03-18 |
2022-03-13 |